PYC Therapeutics (CHIA:PYC) - Stock Price, News & Analysis

PYC Stock Overview

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

About the company

PYC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

PYC Therapeutics Limited Competitors

Clinuvel Pharmaceuticals

ASX:CUV

AU$719.0m

Aroa Biosurgery

ASX:ARX

AU$194.9m

Actinogen Medical

ASX:ACW

AU$65.1m

Radiopharm Theranostics

ASX:RAD

AU$71.7m

Price History & Performance

Summary of all time highs, changes and price drops for PYC Therapeutics
Historical stock prices
Current Share Price	AU$0.14
52 Week High	AU$0.15
52 Week Low	AU$0.052
Beta	0.71
11 Month Change	11.54%
3 Month Change	23.40%
1 Year Change	133.87%
33 Year Change	3.57%
5 Year Change	202.08%
Change since IPO	480.00%

Recent updates

Shareholder Returns

	PYC	AU Biotechs	AU Market
7D	3.6%	-2.0%	0.3%
1Y	133.9%	15.2%	15.1%

Return vs Industry: PYC exceeded the Australian Biotechs industry which returned 15.2% over the past year.

Return vs Market: PYC exceeded the Australian Market which returned 15.1% over the past year.

Price Volatility

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement	10.9%
Biotechs Industry Average Movement	10.6%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	16.6%
10% least volatile stocks in AU Market	3.6%

Stable Share Price: PYC's share price has been volatile over the past 3 months.

Volatility Over Time: PYC's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Rohan Hockings	pyctx.com

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.

PYC Therapeutics Limited Fundamentals Summary

How do PYC Therapeutics's earnings and revenue compare to its market cap?
PYC fundamental statistics
Market cap	AU$699.91m
Earnings (TTM)	-AU$37.73m
Revenue (TTM)	AU$22.06m

32.8x

P/S Ratio

-19.2x

P/E Ratio

Is PYC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYC income statement (TTM)
Revenue	AU$22.06m
Cost of Revenue	AU$0
Gross Profit	AU$22.06m
Other Expenses	AU$59.78m
Earnings	-AU$37.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0081
Gross Margin	100.00%
Net Profit Margin	-171.02%
Debt/Equity Ratio	0%

How did PYC perform over the long term?

See historical performance and comparison

PYC Stock Overview

Rewards

Risk Analysis

PYC Therapeutics Limited Competitors

ASX:CUV

AU$719.0m

ASX:ARX

AU$194.9m

ASX:ACW

AU$65.1m

ASX:RAD

AU$71.7m

Price History & Performance

Recent News & Updates

Insufficient new directors

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Recent updates

Insufficient new directors

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board recently bought AU$81k worth of stock

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes